Impact of different classes of immune-modulating treatments on B cell-related and T cell-related immune response before and after COVID-19 booster vaccination in patients with immune-mediated diseases and primary immunodeficiency: a cohort study.

Michaela KoehmMaximilian KlippsteinStephanie DauthKonstantin HallmannNiko KohmerHarald BurkhardtSandra CiesekGerd GeisslingerHolger F RabenauFrank Behrens

Published in: RMD open (2023)

Patients with IMID on therapeutic B-cell depletion have low anti-S-AB and sVNT values before and after booster vaccination but show significantly higher levels of IGRA compared with other immunosuppressed patients, suggesting an underlying mechanism attempting to compensate compromised humoral immunity by upregulating T-cell responsiveness. PID appears to have a stronger impact on antiviral immune response than csDMARD/bDMARD treatment.

Keyphrases

immune response
end stage renal disease
sars cov
coronavirus disease
ejection fraction
chronic kidney disease
dendritic cells
toll like receptor
signaling pathway
prognostic factors
patient reported outcomes
drug induced
inflammatory response
respiratory syndrome coronavirus
patient reported